Items where authors include "Wadsley, J"

Article

McNamara, MG, Swain, J, Craig, Z et al. (21 more authors) (2023) NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. eClinicalMedicine, 60. 102015. ISSN 2589-5370

Lee, RW, Danson, S, Elliot, M et al. (8 more authors) (2022) Importance of clinical research for the UK's 10-year cancer plan. The Lancet Oncology. ISSN 1470-2045

Ashley, L, Kassim, S, Kellar, I et al. (8 more authors) (2022) Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians. BMJ Open, 12 (2). e060402. ISSN 2044-6055

Walshaw, EG, Smith, M, Kim, D et al. (3 more authors) (2021) Systematic review of health-related quality of life following thyroid cancer. Tumori Journal. ISSN 0300-8916

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. The Lancet Oncology, 22 (7). e288-e289. ISSN 1470-2045

Hall, PS, Swinson, D, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (32 more authors) (2021) Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA oncology, 7 (6). pp. 869-877. ISSN 2374-2437

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 22 (5). pp. 690-701. ISSN 1470-2045

Corrie, PG, Qian, W, Basu, B et al. (31 more authors) (2020) Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122. pp. 1760-1768. ISSN 0007-0920

Craig, Z orcid.org/0000-0001-9930-6648, Swain, J, Batman, E et al. (16 more authors) (2020) NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 10 (2). e034527. ISSN 2044-6055

Jones, RP, Psarelli, E-E, Jackson, R et al. (38 more authors) (2019) Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surgery, 154 (11). pp. 1038-1048. ISSN 2168-6254

Brown, SR, Hall, A, Buckley, H orcid.org/0000-0002-9829-5817 et al. (9 more authors) (2019) Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer, 19 (1). ARTN: 582. ISSN 1471-2407

Primrose, JN, Fox, RP, Palmer, DH et al. (26 more authors) (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology, 20 (5). pp. 663-673. ISSN 1213-9432

Wadsley, J, Gregory, R, Flux, G et al. (6 more authors) (2017) SELIMETRY- A Multicentre I-131 Dosimetry Trial: A Clinical Perspective. British Journal of Radiology, 90 (1073). 20160637. ISSN 0007-1285

Neoptolemos, JP, Palmer, DH, Ghaneh, P et al. (31 more authors) (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, 389 (10073). pp. 1011-1024. ISSN 0140-6736

Feigelson, ED, Townsley, LK, Broos, PS et al. (16 more authors) (2013) Overview of the massive young star-forming complex study in infrared and X-ray (MYStIX) project. Astrophysical Journal, Supplement Series, 209 (2). 209 - 226. ISSN 0067-0049

Middleton, G, Brown, S, Lowe, C et al. (17 more authors) (2013) A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European Journal of Cancer, 49 (16). 3507 - 3516. ISSN 0959-8049

Seymour, MT, Brown, SR, Middleton, G et al. (18 more authors) (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet Oncology, 14 (8). 749 - 759. ISSN 1470-2045

Conference or Workshop Item

Hall, P, Swinson, D, Lord, S et al. (23 more authors) (2019) Optimizing Chemotherapy for Frail and Elderly Patients with Advanced Gastroesophageal Cancer (aGOAC): the GO2 Phase III Trial. In: 2019 NCRI Cancer Conference of National Cancer Research Institute, 03-05 Nov 2019, Glasgow, Scotland, UK.

Proceedings Paper

McNamara, MG, Swain, J, Craig, Z et al. (11 more authors) (2019) NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

Hall, PS, Swinson, D, Waters, JS et al. (17 more authors) (2019) Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, USA. American Society of Clinical Oncology .